

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**EFFECTIVE DATE OF THE CAPITAL REORGANISATION
AND COMPLETION OF THE CONNECTED TRANSACTION
FOR ALTERATION TO THE TERMS OF THE EXISTING
CONVERTIBLE BONDS**

Reference is made to the circulars (the “**Circular**”) of Wai Chun Bio-Technology Limited (the “**Company**”) dated 28 March 2025, the announcements of the Company dated 23 April 2025, 21 May 2025, 21 August 2025, 11 September 2025, 29 September 2025, 28 October 2025 and 13 November 2025 (the “**Announcements**”). Unless otherwise defined or the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcements.

CAPITAL REORGANISATION BECOMING EFFECTIVE

The Board is pleased to announce that a copy of the order of the Grand Court confirming the Capital Reduction and the minute approved by the Grand Court containing the particulars required under the Companies Act with respect to the Capital Reduction were filed and duly registered with the Registrar of Companies in the Cayman Islands and that all conditions of the Capital Reorganisation as set out in the Circular have been fulfilled. Accordingly, the Capital Reorganisation will become effective and the dealings in the New Ordinary Shares will commenced at 9:00 a.m. on Thursday, 20 November 2025 (Hong Kong time).

COMPLETION OF ALTERATION OF TERMS

Upon the Capital Reorganisation becoming effective, the connected transaction for alteration to the terms of the Existing Convertible Bonds will be completed on Thursday, 20 November 2025 (Hong Kong time).

EXCHANGE OF SHARE CERTIFICATES

The Capital Reorganisation will not affect any of the rights of the existing Shareholders. All existing share certificates of the Company will continue to be evidence of title to the shares and continue to be valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates for the New Ordinary Shares after the Capital Reorganisation takes effect. Immediately following the Capital Reorganisation becoming effective, new share certificates will be issued bearing the par value of HK\$0.01 per New Share.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Chief Executive Officer

Hong Kong, 19 November 2025

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and three independent non-executive Directors, namely Mr. Wang Ziniu, Ms. Xu Huiling and Mr. Wong Po Keung.